Hepatitis C is a serious viral infection. Many people who get hepatitis C may not feel sick at first. If the virus is not treated, it can damage your liver, make you feel tired all the time, and increase your chance of developing diabetes and other medical conditions. For many people, hepatitis C is treated and cured with an eight-to-12-week course of medication.
Several years ago, the federal government approved a new class of drugs called direct-acting antivirals (DAAs) to treat hepatitis C. These drugs can help many people, regardless of how long they’ve had the virus or the damage it has caused.
On Jan. 1, 2023, Texas Medicaid made the drug Mavyret (glecaprevir/pibrentasvir) the preferred DAA treatment for Medicaid patients. Mavyret is made by AbbVie who has partnered with the Texas Health and Human Services Commission to reduce hepatitis C in Texas.
Mavyret is a prescription drug used to treat adults and children 3 years old and older with chronic hepatitis C. The drug is usually taken for eight weeks but can be taken longer as decided by your health care provider. Your healthcare provider can prescribe Mavyret for the whole length of your treatment, so you do not need to ask for refills.
If you have hepatitis C and are enrolled in Texas Medicaid, talk to your healthcare provider to find out if DAA treatment with Mavyret is right for you.
Community First Resources:
Email ProviderRelations@cfhp.com or call 210-358-6294.